An Improved Solution to Combat Heart Failure

Gen I catheter based pump

Gen II wireless powered chronic implant

Motor controller

Latest News

Second Heart Assist, Inc. Announces Issuance of 20 New U.S. Patent Claims Covering its Circulatory Assist Device Technology Platform

March 16th, 2023, Salt Lake City, Utah and Mission Viejo, CA - Second Heart Assist, Inc. has announced that it has obtained patent no. U.S. 11,602,627 on March 14th, 2023 from the US Patent and Trademark Office Titled “Circulatory Assist Pump” with 20 new patent...

4Q 2021 Stakeholder Update

4Q 2021 Stakeholder Update Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe...

Second Heart Assist Files Patent for Electro-Activated Shape Changing Impeller for Circulatory Assist Devices

Salt Lake City, Utah and Irvine, CA Nov. 17th, 2020 (PR Distribution) -- Second Heart Assist, Inc.  has filed a patent application with the United States Patent and Trademark Office (USPTO) covering numerous claims for the utilization of electro-active polymers and...

Second Heart Assist Announces Successful Completion of Long-Duration Pre-Clinical Studies

First Long-Duration Clinical Studies in Cardio-Renal Syndrome Patients Now Scheduled to Take Place July 2020 in Tbilisi, Georgia NEWS PROVIDED BY Second Heart Assist, Inc. June 22nd, 2020 7:00am ET  Salt Lake City, Utah, June 22nd, 2020 /PRDistribution/ -- Second...

Second Heart Assist to Present Clinical Data at American Society for Artificial Internal Organs 66th Annual Conference

Salt Lake City, UT (April 30th, 2020) - Following blind peer review, Second Heart Assist's clinical data presentation has been selected for oral presentation at the American Society of Artificial Organs (ASAIO) 66th annual conference, scheduled to be held entirely...
CAUTION Disclaimer and Warning: Products described on this web site are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. Investigational use only in countries where investigation is permitted by law and proper filings have been made and appropriate regulatory clearances have been granted. Any use of the product(s) must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent procedures followed. For other countries product is only available for laboratory investigation by credentialed institutions and investigators with proper clearances with a research agreement in place with a study sponsor. NOT AVAILABLE FOR SALE.